Physician profile
Aneley Hundae
NPI 1659551356
$14,909.34
in general payments reported to CMS, 2019-2025
24 companies · $1,882 in 2025
The $1,882 reported for 2025 was more than what 83% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $598 · 2020: $580 · 2021: $702 · 2022: $1,729 · 2023: $3,219 · 2024: $6,199 · 2025: $1,882.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,256 · Travel and Lodging: $5,043.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,256.49 |
| Travel and Lodging | $5,042.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $7,339.03 | 2019-2025 | Mitraclip, Accent, Jot Dx |
| Boston Scientific Corporation | $3,540.69 | 2019-2025 | Watchman Access System, Watchman Flx, Lux-Dx Insertable Cardiac Monitor |
| Biotronik INC. | $801.43 | 2022-2025 | Biomonitor, Acticor 7 Vr-T Dx, Amvia Edge |
| Merck Sharp & Dohme LLC | $419.10 | 2021-2025 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $398.60 | 2019-2025 | Lifevest |
| Philips North America LLC | $389.84 | 2022-2025 | (5091) Amb Mon & Diag Und, (Cm9) Amb Mon & Diag Und, Event |
| Amgen INC. | $303.99 | 2021-2025 | Repatha, Repatha |
| Astellas Pharma US INC | $297.99 | 2020-2021 | |
| Alnylam Pharmaceuticals INC. | $262.52 | 2023-2025 | Amvuttra, Onpattro |
| Pfizer INC. | $182.28 | 2020-2025 | |
| Sanofi-Aventis U.S. LLC | $157.57 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $145.54 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $118.22 | 2020-2022 | |
| Cvrx, INC. | $111.86 | 2024-2025 | Barostim Neo System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.00 | 2019-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $65.59 | 2019-2023 | Opsumit, Uptravi |
| Medtronic, INC. | $58.75 | 2021-2023 | Azure Xt Dr Mri Surescan, Linq II |
| Atricure, INC. | $58.48 | 2023-2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Scpharmaceuticals INC. | $46.40 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $37.12 | 2021-2023 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $33.79 | 2020-2022 | |
| Heartflow, INC. | $23.50 | 2025 | |
| Edwards Lifesciences Corporation | $21.33 | 2020 | |
| G Medical Diagnostic Services, INC. | $11.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aneley Hundae listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.